CJC-1295 no-DAC (Mod GRF 1-29) 5 mg + Ipamorelin 5 mg. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
Food, and carbohydrate in particular, raises insulin and blunts the growth-hormone pulse these compounds are meant to trigger. The two windows where you are naturally fasted and GH release is highest are early sleep and first thing on waking, which is why those are the only two sensible times.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 200 mcg | daily | 0.06 mL | 6 u | 14 | 2.8 mg |
| Weeks 3–4 | 400 mcg | daily | 0.12 mL | 12 u | 14 | 5.6 mg |
| Week 5 onward per 4 weeks from here on |
600 mcg | daily | 0.18 mL | 18 u | 28 | 16.8 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Low reported | 200 mcg | 1× daily · 100 mcg of each compound | 0.06 mL | 6 u | 50 doses |
| Standard | 400 mcg | 1–2× daily · 200 mcg of each compound | 0.12 mL | 12 u | 25 doses |
| Upper reported | 600 mcg | 1–2× daily · 300 mcg of each compound | 0.18 mL | 18 u | 16 doses |
A GHRH analogue paired with a selective ghrelin receptor agonist — the pairing rationale is that the two receptors act synergistically on GH release. A 10 mg vial holds 5 mg of each; a 200 mcg dose therefore delivers 100 mcg of each.
Buy CJC-1295 / Ipamorelin BlendPaid affiliate links.
Adding 3 mL of bacteriostatic water to a 10 mg vial gives 3.33 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for CJC-1295 / Ipamorelin Blend run from 200 mcg to 600 mcg, typically 1× daily (100 mcg each). This site lists each figure with the source it came from rather than giving a single recommended number.
At 3.33 mg/mL, a 200 mcg dose is 6 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 50 doses.
CJC-1295 / Ipamorelin Blend is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
These act on two different receptors, which is the entire reason the blend exists. CJC-1295 is a GHRH analogue; ipamorelin is a selective ghrelin-receptor agonist. They stimulate growth hormone release through separate pathways.
This is the one blend on the site where the combination has a mechanistic argument rather than just convenience — the two pathways are complementary, and the pairing is standard enough that the separate vials are rarely used alone. Ipamorelin was specifically developed to avoid the cortisol, prolactin and appetite effects of earlier ghrelin agonists such as GHRP-6.
Compounds in the same class, or browse the full catalogue.
An equal-parts repair and anti-inflammatory pairing — 10 mg of each in a 20 mg vial, so every dose splits evenly down the middle a…
A fixed-ratio combination vial. Because the components are pooled at a fixed ratio, you cannot titrate one without moving the othe…
Every compound compared in one table: dose range, how often, half-life and evidence tier.
Need this on one page to print, screenshot or send?
Make a dose card →